Balance Sheet Account Details (Tables)
|
6 Months Ended |
Jun. 30, 2023 |
|---|
| Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
| Schedule of Accounts Receivable |
| | | | | | | | | | | | | | June 30,
2023 | | | December 31,
2022 | | Accounts receivable, net: | | | | | | Accounts receivable, trade | $ | 7,875,000 | | | | $ | 7,315,000 | | | Allowance for credit losses | (262,000) | | | | (293,000) | | | $ | 7,613,000 | | | | $ | 7,022,000 | |
|
| Schedule of Allowance for Credit Losses |
Changes to the allowance for credit losses during the six months ended June 30, 2023 were as follows: | | | | | | | Allowance for Credit Losses | | Balance as of January 1, 2023 | $ | (293,000) | | | Provision for expected credit loss | (5,000) | | | Write-offs and payments | 36,000 | | Balance as of June 30, 2023 | $ | (262,000) | |
|
| Schedule of Components of Inventories |
The components of inventories are as follows: | | | | | | | | | | | | | | June 30,
2023 | | December 31,
2022 | | Inventory: | | | | | Raw materials | $ | 6,204,000 | | | $ | 5,319,000 | | Work in process | 10,577,000 | | | 7,055,000 | | | Finished goods | 15,672,000 | | | 17,387,000 | | | $ | 32,453,000 | | | $ | 29,761,000 | |
|
| Schedule of Finite-Lived Intangible Assets |
Intangible assets that are subject to amortization consisted of the following for the periods presented: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | June 30, 2023 | | December 31, 2022 | | | Gross Carrying Amount | | Accumulated Amortization | | Net Carrying Amount | | Gross Carrying Amount | | Accumulated Amortization | | Net Carrying Amount | | Trade name | | $ | 2,630,000 | | | $ | (815,000) | | | $ | 1,815,000 | | | $ | 2,630,000 | | | $ | (552,000) | | | $ | 2,078,000 | | | Customer relationships | | 4,150,000 | | | (1,587,000) | | | 2,563,000 | | | 4,150,000 | | | (1,172,000) | | | 2,978,000 | | | Developed technology | | 41,600,000 | | | (8,521,000) | | | 33,079,000 | | | 41,600,000 | | | (5,615,000) | | | 35,985,000 | | | Intangibles, net | | $ | 48,380,000 | | | $ | (10,923,000) | | | $ | 37,457,000 | | | $ | 48,380,000 | | | $ | (7,339,000) | | | $ | 41,041,000 | |
|
| Schedule of Accrued Liabilities |
Accrued expenses consist of the following: | | | | | | | | | | | | | June 30,
2023 | | December 31,
2022 | | Compensation expenses | $ | 5,917,000 | | | $ | 7,002,000 | | | Customer deposits | 17,000 | | | 17,000 | | | Taxes payable | 897,000 | | | 825,000 | | | Insurance | 125,000 | | | 613,000 | | | Professional fees and royalties | 153,000 | | | 210,000 | | | Warranty liabilities | 640,000 | | | 489,000 | | | Accrued clinical study fees | 150,000 | | | 250,000 | | | Other | 417,000 | | | 1,146,000 | | | Total | $ | 8,316,000 | | | $ | 10,552,000 | |
|